Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide. The ability to accurately assess the risk of CVD is crucial in enabling timely intervention and management. This article will delve into the current strategies for risk assessment in CVD, highlighting their strengths and limitations.
The Framingham Risk Score (FRS) and the American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Equations are widely used models. They incorporate factors such as age, gender, cholesterol levels, blood pressure, diabetes, and smoking status. However, their predictive accuracy can be limited, particularly in diverse populations.
Novel risk factors such as high-sensitivity C-reactive protein (hs-CRP), lipoprotein(a), and coronary artery calcium (CAC) scoring have emerged. These can potentially enhance risk prediction, especially in intermediate-risk individuals. Yet, their routine use in clinical practice is still under debate due to cost-effectiveness and standardization issues.
With advances in genomics, genetic risk scores comprising multiple CVD-associated single nucleotide polymorphisms have been developed. They offer the advantage of being stable throughout life. However, their incremental value over traditional risk factors is yet to be conclusively determined.
Imaging techniques such as coronary computed tomography angiography (CCTA) and cardiac magnetic resonance imaging (MRI) provide direct visualization of the heart and vessels. They can detect subclinical atherosclerosis, but their role in routine risk assessment is still evolving due to concerns about radiation exposure and cost.
In conclusion, while traditional risk assessment models remain the cornerstone of CVD risk prediction, novel biomarkers, genetic risk scores, and imaging techniques may enhance risk stratification, particularly in certain subgroups. Further research is needed to optimally integrate these tools into routine clinical practice.
1.
For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.
2.
FDA Advisors Recommend Galleri Multicancer Blood Test
3.
Women who miss their first mammogram face higher risk of breast cancer death, study finds
4.
Thriving while surviving: Understanding the social needs of cancer survivors
5.
Can Accelerated Salvage RT Improve Prostate Cancer Control?
1.
Fatigue and Work Participation in Blood Disease: A Comprehensive Review
2.
First-Line Immuno-Hematology Examinations: Essential Diagnostic Tools for Patient Care
3.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
4.
The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside
5.
Childhood Cancer Prevention Through Modifiable Exposure Reduction
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Understanding Common Causes of Abnormal Blood Counts
4.
Hematologic Fatigue and Work Function: Clinical Implications, Pathophysiology, and Management
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation